Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Morin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 2/20 | 1.00 |
| ▸ | MEN1 known ✓ | O00255 | 8/20 | 0.97 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 4/20 | 0.97 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.97 |
| ▸ | SYK known ✓ | P43405 | 3/20 | 0.97 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.73 |
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.73 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.73 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.73 |
| ▸ | GSK3A known ✓ | P49840 | 2/20 | 0.73 |
| ▸ | GSK3B known ✓ | P49841 | 2/20 | 0.73 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.67 |
| ▸ | PIK3CG known ✓ | P48736 | 2/20 | 0.66 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.66 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.65 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.65 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.65 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.65 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morin SCHEMBL7116848 | 1.00 | MPG (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL294933 | 1.00 | MPG (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL15106661 | 1.00 | MPG (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL29435805 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL29929115 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL10335390 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL19984 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL21874430 | 0.97 | MEN1 (0.97) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL8165525 | 0.93 | MEN1 (0.89) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL5248628 | 0.91 | MEN1 (0.89) | MPGTHRBMEN1KMT2AXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340505-A1 | SOLID-STATE FORM OF HYDRATE OF CALCIUM OXYBATE, METHOD OF MAKING AND USE | MACFARIAN SMITH LTD (GB) | 2025-11-06 | — | — | US | claimed |
| EP-4355306-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | Helm AG (DE) | 2024-04-24 | — | — | EP | claimed |
| US-20230293430-A1 | FORMULATIONS INCLUDING 5-[3-(3-HYDROXYPHENOXY)AZETIDIN-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE | MYLAN PHARMA UK LIMITED (GB) | 2023-09-21 | — | — | US | claimed |
| WO-2022263510-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | HELM AG (DE) | 2022-12-22 | — | — | WO | claimed |
| WO-2022106893-A1 | SOLID-STATE FORM OF THE MONOHYDRATE OF CALCIUM OXYBATE, METHOD FOR ITS PREPARATION AND THERAPUTIC USE | JOHNSON MATTHY PUBLIC LIMITED COMPANY (GB) | 2022-05-27 | — | — | WO | claimed |
| US-20260027058-A1 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | CHEMO RES S L (ES) | 2026-01-29 | — | — | US | disclosed |
| US-20260021110-A1 | METHODS OF ORAL CONTRACEPTION BY CONTROLLED RELEASE OF DIENOGEST AND ETHYNYL ESTRADIOL | CHEMO RES S L (ES) | 2026-01-22 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4611738-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Lykos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12409142-B2 | Modified release oral contraceptive composition | CHEMO RESEARCH, S.L. (ES) | 2025-09-09 | — | — | US | disclosed |
| EP-4547038-A1 | FEED FOR ANADROMOUS FISH, METHOD FOR PRODUCING IT, METHOD OF INCREASING SEAWATER TOLERANCE, GROWTH AND FEED INTAKE OF ANADROMOUS FISH, FISH FEED FOR USE IN PREVENTING OR REDUCING SEVERITY OF CATARACTS | Nutreco IP Assets B.V. (NL) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129043-A1 | FASORACETAM CRYSTALLINE FORMS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2022263510-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | HELM AG (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220315694-A1 | EPOXY RESIN COMPOSITION, GAS BARRIER FILM, AND LAMINATE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-10-06 | — | — | US | disclosed |
| EP-4058422-A1 | IMPROVED UREA-BASED BLEND COMPOSITION AND METHOD FOR THE MANUFACTURE THEREOF | Yara International ASA (NO) | 2022-09-21 | — | — | EP | disclosed |
| US-20220204963-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2022-06-30 | — | — | US | disclosed |
| EP-4015577-A1 | EPOXY RESIN COMPOSITION, GAS BARRIER FILM, AND LAMINATE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-06-22 | — | — | EP | disclosed |
| EP-3973565-A1 | COMPOSITION AND PROCESS FOR SELECTIVELY ETCHING A HARD MASK AND/OR AN ETCH-STOP LAYER IN THE PRESENCE OF LAYERS OF LOW-K MATERIALS, COPPER, COBALT AND/OR TUNGSTEN | BASF SE (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220056067-A1 | NOVEL CRYSTALLINE FORMS OF AN NRTTI COMPOUND | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129043-A1 | FASORACETAM CRYSTALLINE FORMS | FAH, FASN, FAHD1 | THRB 3727/4885MEN1 4495/4885HDAC6 294/4885 |
| US-20260021110-A1 | METHODS OF ORAL CONTRACEPTION BY CONTROLLED RELEASE OF DIENOGEST AND ETHYNYL ESTRADIOL | SHBG, ESRRG, ESR2 | THRB 1280/4885MEN1 983/4885HDAC6 4625/4885 |
| US-20220204963-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | THRB 4221/4885MEN1 2811/4885HDAC6 241/4885 |
| US-20260027058-A1 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | SHBG, HSD17B11, PGR | THRB 532/4885MEN1 1408/4885HDAC6 1962/4885 |
| US-20220056067-A1 | NOVEL CRYSTALLINE FORMS OF AN NRTTI COMPOUND | ADAR, NT5C3B, RNMT | THRB 4276/4885MEN1 4666/4885HDAC6 507/4885 |
| US-20250340505-A1 | SOLID-STATE FORM OF HYDRATE OF CALCIUM OXYBATE, METHOD OF MAKING AND USE | CA2, CA3, ORAI1 | THRB 1918/4885MEN1 1290/4885HDAC6 2844/4885 |
| US-20230293430-A1 | FORMULATIONS INCLUDING 5-[3-(3-HYDROXYPHENOXY)AZETIDIN-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE | ADRB2, ADRA2C, ADRA2A | THRB 1488/4885MEN1 3681/4885HDAC6 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.